Michiel Dalinghaus is pediatric cardiologist at the Sophia Children’s Hospital/Erasmus MC, Rotterdam. He is medical director of Pediatric Heart Failure & Transplantation, which is the national referral centre for (end-stage) heart failure and transplantation in children.
His research has focussed on the clinical characterization of severe/end-stage heart failure in children. The last 10 years he led nationwide studies, which characterized risk factors for outcome in children with dilated cardiomyopathy and genetics of disease (CARS I&II;supported by the Stichting Hartedroom & NHF) and acted as PI for DCM in a European study on pharmacological aspects of enalapril (LENA consortium; EU-FP7 funded). In cooperation with prof Jolanda van der Velden (VuMC) a bed-to-bench study to characterize abnormalities of contractile properties of cardiac myocytes in pediatric end-stage heart failure was performed. This cooperation will continue within the Double Dose consortium, allowing to further unravel underlying mechanisms in pediatric cardiomyopathy.